同源重组修复缺陷检测在前列腺癌患者中的治疗意义(下篇)
本专家共识由多学科专家组于2023至2024年制定,聚焦转移性去势抵抗性前列腺癌(mCRPC)中胚系与体细胞同源重组修复(HRR)检测的应用,并基于近期III期试验及PARP抑制剂后续监管批准,阐述基因检测如何改善mCRPC治疗策略以延长生存。
要点
- 专家组就mCRPC中胚系与体细胞HRR检测的应用形成共识意见。
- 基因检测可基于近期III期试验指导PARP抑制剂治疗选择。
- 并非所有mCRPC患者均接受可延长生存的全身治疗,需优化治疗选择。
核心结论
- 基因检测可基于近期III期试验及PARP抑制剂后续监管批准,促成改善且延长生存的mCRPC治疗策略。
研究设计与样本
- 本指南为两部分组成的专家意见,由2023至2024年召集的多学科专家组制定,成员来自肿瘤内科、泌尿外科、放射肿瘤科、病理科、医学基因组学及基础科学。
- 本指南提供关于利用胚系与体细胞检测发现mCRPC患者HRR变异的专家共识意见。
主要发现
- 并非所有mCRPC患者均接受可延长生存的全身治疗,凸显优化mCRPC治疗选择的必要性。
- 下篇基于近期III期试验及PARP抑制剂后续监管批准的综述,阐述基因检测如何改善mCRPC治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. SUBJECTS/METHODS: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science. RESULTS/CONCLUSIONS: In this second part, we highlight how genetic testing can lead to improved, life-prolonging mCRPC therapeutic strategies based on a review of the recent phase III trials and subsequent regulatory approvals for PARP inhibitors in mCRPC.
引用
- Serritella AV, Taylor A, Haffner MC, et al. Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). Prostate Cancer Prostatic Dis. 2024. PMID: 39333696. doi:10.1038/s41391-024-00887-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。